AstraZeneca

NEWS DESK

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

News Desk 1 12/11/2024 0

AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the

NEWS DESK

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

News Desk 2 21/05/2024

Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade. To drive sustained growth […]

NEWS DESK

DoH Inks Strategic Collaboration with Abu Dhabi Health Data Services and AstraZeneca to Combat Breast Cancer

News Desk 2 15/05/2024

During Abu Dhabi Global Healthcare Week (ADGHW), the Department of Health – Abu Dhabi (DoH), the regulator of the Emirate’s healthcare sector, signed a Memorandum of Understanding (MoU) with M42’s Abu Dhabi Health Data Services (ADHDS), a premier digital healthcare solutions company and AstraZeneca, a global science-led biopharmaceutical company. The entities will

NEWS DESK

M42 signs groundbreaking agreement with AstraZeneca

News Desk 2 06/05/2024

M42, a first-of-its-kind tech-enabled global health powerhouse, has signed a groundbreaking agreement with AstraZeneca, a global leader in science-led biopharmaceuticals, to advance preventive healthcare and next-generation precision medicine. As AstraZeneca’s clinical genomics partner of choice in the Middle East region, M42 will conduct sequencing of hereditary breast